After acknowledging the potential role of the neutral amino acid transporters addressed here on the hallmarks of cancer, the focus of researchers and pharmaceuticals on ASCT2 and LAT1 clinical relevance is to be expected [130] (Figure 5). Here, SLC1A5 is linked to cancer.